Case study

Specialist PV support transforms safety for orphan medicinal products

Explore the case study to learn how Cencora supported a UK company developing two orphan-designated, centrally authorized drugs after challenges with a prior provider.

Key highlights

Following a successful safety database migration, Cencora delivered an integrated, single-provider pharmacovigilance model across the EU, UK, and Switzerland, including QPPV coverage, local PV set-up, PSMF and EudraVigilance maintenance, case management, and clinical trial safety oversight. The outcome was improved compliance, streamlined operations, and strengthened audit readiness.